RARA and hepatocellular carcinoma: ATRA or its chemical derivatives have long been tested as candidates for treatment of HCC as single reagent or in combination with other clinically used drugs7,8, the results was, however, far to be satisfactory, which could be partially attributed to the perturbation of AFP and the resultant dysregulation of RAR target genes.